Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

This study is testing an experimental medicine called VERVE-102, which uses gene-editing technology to help lower high cholesterol levels in the blood. It is designed to change how the liver produces a specific protein, potentially offering a new way to manage heart health for those who need extra help lowering their LDL-C, or 'bad' cholesterol.

You may be eligible if you have a confirmed diagnosis of inherited high cholesterol or have developed heart disease at an unusually young age. The doctors will perform specific tests to ensure your liver and overall health are suitable for this trial.

Participants will receive a single dose of the study medicine and will be carefully monitored by the research team to see how their body reacts and how the medicine affects their cholesterol. You will have regular visits with the study doctors to prioritize your safety and track your health progress throughout the trial.

The study is currently recruiting patients at research centers in Dothan, Alabama; Pomona, California; and Boca Raton, Florida. Being in the early phase of testing, this study focuses on gathering essential safety information.